Phase 2 N=92 A Study of DER 45-EV Gel to Treat Rosacea
Rosacea
Primary: Investigator Global Assessment (IGA) Improvement From Baseline — 37.5; 20.0; 53.3 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=34 Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
Parkinson's Disease (PD)
Primary: Number of Patients With at Least One Adverse Event — 3; 1; 1; 2 Number of patients
Phase 2 N=62 Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction
Anxiety Disorder · Breast Cancer · Cognition Disorders
Primary: Retention — 71.0; 80.7 percentage of participants
Phase 1 N=12 Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
Parkinson
Primary: Cmax - Maximum Observed Plasma Concentration — 635.0; 238.2 ng/mL
Phase 4 N=28 Bioenergetic Alterations After Exenatide Administration
Healthy
Primary: Change in Energy Intake Measured Before Treatment and at the End of Treatment. — -167 kcal/d — p=0.001
Phase 2 N=90 Compression Device Versus 4-layer Compression System
Leg Ulcers
Primary: Safety Measured by the Number of Subjects With Adverse Events (Including Any Deterioration of Ulcer) — 33; 47 Number of Subjects with Adverse Events
Phase 2 N=35 A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
HCV Infection
Primary: Persistence of Resistance-Associated Variants and Phenotypic Resistance — 4; 0; 2; 0 participants
Phase 3 N=840 Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Participants With Sustained Accumulation of Disability (SAD) — 21.13; 12.71 percentage of participants — p=0.0084
Phase 3 N=600 Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
Parkinson's Disease
Primary: Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo, — -56.0; -96.3; -91.3; -85.9 minutes
N/A N=27 A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients
ALS (Amyotrophic Lateral Sclerosis)
Primary: BCI System Usage by the ALS Patient — 171 days
Phase 1 N=18 Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate
Epilepsy
Primary: Cmax (BIA 2-005) — 10973; 11044; 11022 ng/mL
Phase 2 N=12 Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
Chronic Hepatitis C Infection
Primary: Maximum Plasma Concentration (Cmax) of ABT-267 Following Monotherapy on Day 1 — 1.66; 41.0 ng/mL
N/A N=144 Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Pressure Ulcers · Spinal Cord Injuries
Primary: Percent of Possible Self-Reported Skin Care Behaviors — 73.8; 74.1; 83.5; 79.5 % of Possible Self-Reported Behaviors
Phase 1 N=64 A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
Parkinson Disease
Primary: Adverse Events (AEs) — 0; 0; 2; 0 Number of Adverse Events
Phase 1 N=43 Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine
Epilepsy
Primary: Cmax (BIA 2-093) - the Maximum Plasma Concentration — 18601; 14591 ng/mL